Apremilast
Category
Pharmaceutical Actives & Precursors
Sub-Category
Active Pharmaceutical Ingredients (APIs)
Description : Apremilast (CAS No: 608141-41-9) represents a pivotal advancement in the global speciality chemicals and biopharmaceutical sectors as a small-molecule phosphodiesterase 4 (PDE4) inhibitor, currently valued at approximately USD 2.67 billion with a projected growth to USD 3.95 billion by 2032. The market is increasingly driven by the robust demand for targeted oral immunomodulatory therapies, particularly for chronic inflammatory conditions such as moderate to severe plaque psoriasis and psoriatic arthritis, where the 30 mg dosage strength remains the dominant therapeutic standard. Technical advancements in the synthesis of this crystalline active substance focus on optimising the six-step reaction process to manage its inherent chirality and polymorphism, specifically ensuring the consistent production of the stable polymorphic B form to meet stringent international pharmacopoeial and regulatory standards. Furthermore, the strategic shift towards the Asia-Pacific region, coupled with the expansion of label indications and the entry of high-quality generic alternatives, is reshaping the competitive landscape for CDMOs and API manufacturers who prioritise enantiomeric purity and rigorous analytical validation via HPLC, NMR, and XRD techniques. We are an established Apremilast api supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Apremilast COA/TDS/SDS region-specific regulatory support. reliable lead times, worldwide supply chain capabilities








